Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01153490 · ClinicalTrials.gov registry record · Phase 4
Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine
A Phase 4 study of Cannabis Dependence, sponsored by Northwell Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 124
- Enrollment target
- 2
- Study locations
NCT01153490 is a Phase 4 study of Cannabis Dependence that has completed, run by Northwell Health. The registered enrollment target is 124 participants, roughly in line with the 120-participant average among 12 other Cannabis Dependence trials with a reported enrollment target. The trial reports 2 study locations across 1 state.
The verdict
NCT01153490, a Phase 4 study of Cannabis Dependence, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 124 participants
- Enrollment target
- 2
- Study locations
Study Summary
Cannabis is the most used illicit substance in the United States. Previous studies suggest that atypical antipsychotics decrease the frequency and the amount of substance use in subjects with and without psychotic illness. So far, there are no controlled studies assessing the effectiveness of atypical antipsychotics for decreasing cannabis and other substance use in individuals with cannabis use disorders. The investigators postulate that the atypical antipsychotic quetiapine ER is an effective agent for improving substance use outcomes in subjects with cannabis use disorders. In this pilot study, the investigators will test this hypothesis in heavy cannabis users (i.e., individuals who are cannabis dependent and smoke three times or more per week). Because 50% of these heavy cannabis users report histories of psychotic experiences (i.e., attenuated positive symptoms) while smoking and are at risk for recurring psychotic symptoms, the investigators will focus this pilot clinical trial on this subgroup of cannabis users in order to increase the risk/benefit ratio of this study and target a population that may also benefit from the antipsychotic effect of quetiapine ER. Considering the lack of controlled studies assessing the efficacy of atypical antipsychotics in heavy cannabis users, assessing the effectiveness of an atypical antipsychotic medication on substance use and clinical outcomes in this population is critical for improving the prognosis of these individuals. Thus, the aims of this randomized, double-blind, placebo-controlled study are to assess the efficacy of an atypical antipsychotic (quetiapine ER) in 120 subjects with cannabis dependence, a recent history (within a year) of attenuated psychotic symptoms, and using cannabis 3 times or more per week for: (1) decreasing the use of cannabis and other substances; and (2) preventing the recurrence of psychotic experiences. The investigators will also assess the effects of quetiapine ER on craving and mood,
Conditions Studied
Interventions
- BEHAVIORAL Behavioral Intervention
Study Locations (2)
New York
- The Zucker Hillside Hospital - Glen Oaks
- General Clinical Research Center - Manhasset
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2010-10-22 |
| Est. Completion | 2012-08-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01153490
The ClinicalTrials.gov registry entry for NCT01153490 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 120-participant average among 12 other Cannabis Dependence trials with a reported enrollment target. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cannabis Dependence appearing as the primary indexed condition, and to 1 intervention - of which Behavioral Intervention is the first listed.
NCT01153490 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01153490 about?
NCT01153490 is a clinical study titled "Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine". Cannabis is the most used illicit substance in the United States. Previous studies suggest that atypical antipsychotics decrease the frequency and the amount of substance use in subjects with and without psychotic illness. So far, there are no controlled studies assessing the effectiveness of atypic...
What is the current status of trial NCT01153490?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 124 participants. The study started on 2010-10-22. Estimated completion is 2012-08-06.
What conditions does trial NCT01153490 study?
This clinical trial studies the following conditions: Cannabis Dependence.
What interventions are being tested in trial NCT01153490?
The interventions under investigation include: Behavioral Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT01153490?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01153490 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cannabis Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reducing Cannabis Overuse With Prazosin
COMPLETED · Phase 4
-
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
RECRUITING
-
Neuroimaging of Adolescent Cannabis Use Treatment
RECRUITING · NA
-
Breathwork-assisted Treatment for Cannabis Use Disorder
ACTIVE NOT RECRUITING · NA
-
Targeting Tobacco Cessation During Treatment for Cannabis Use Disorders
COMPLETED · NA
-
Neurobehavioral Measurement of Substance Users in Outpatient Treatment Setting
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.